logo-loader

Arcturus Therapeutics stock rockets higher amid expansion of Ultragenyx collaboration

Last updated: 01:45 20 Jun 2019 AEST, First published: 00:42 20 Jun 2019 AEST

Arcturus scientist in a lab
The partnership will pay Arcturus for major milestones reached in the development process

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) shares surged after the messenger RNA medicine company announced Wednesday the continuation of its collaboration with Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

The companies plan to discover and develop mRNA, DNA and small interfering RNA therapeutics to target a slate of rare diseases.

Arcturus shares jumped nearly 42% to $8.19. Shares of Ultragenyx, a large-cap pharmaceutical company, ticked up 0.6% to $62.70.

READ: Melinta stock doubles on FDA approval of a supplemental new drug application for BAXDELA to treat pneumonia

The partnership will pay Arcturus for major milestones reached in the development process. The two companies have been working together since October 2015.

The first such treatment is designed to treat Glycogen Storage Disease Type III, a hereditary disorder that impairs the body’s ability to break down carbohydrates.

“The expansion of the collaboration with Ultragenyx underscores the partnership’s early successes and ongoing commitment,” CEO Joseph Payne said. “Our expertise in the discovery, early development and manufacturing of RNA medicines aligns well with Ultragenyx’s proven clinical development and commercial experience in rare diseases.”

Arcturus Therapeutics is an RNA medicines company based in San Diego, California. Itstreatment pipeline includes therapies for Ornithine Transcarbamylase Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, and non-alcoholic steatohepatitis.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

10 hours, 2 minutes ago